That's why General Motors' (GM) Chevy Volt won top marks for safety in small cars.
The Volt was named "Top Safety Pick Plus" Wednesday by the Insurance Institute for Highway Safety, because besides earning an "acceptable" rating in an actual crash test, the hybrid electric vehicle also has an optional forward collision warning system. It was the only car out of the 12 models tested to have the crash prevention technology.
IIHS submitted twelve small vehicles through a tough crash test called the "small overlap front test." In the test, 25 percent of the vehicle's front end on the driver's side strikes a rigid barrier at 40 miles per hour. It simulates a common head-on collision, when only part of the bumper connects with another car, telephone pole, or tree.
Top 5 Value Stocks To Buy Right Now: Prudential Public Limited Company(PUK)
Prudential plc provides retail financial products and services, and asset management services to individuals and businesses in Asia, the United States, and the United Kingdom. It offers savings, protection, investment, and unit-linked products; manages investments across a range of asset classes for internal, retail, and institutional clients; manages onshore mutual funds; and provides retirement planning, consumer and Islamic finance, and health solutions. The company also provides retirement savings and income solutions; variable annuities; fixed and fixed index annuities; term life, universal life, and variable universal life insurance; permanent individual life insurance; and institutional products, such as guaranteed investment contracts, funding agreements, and medium term note funding agreements. In addition, it offers pensions and annuities; investment plans; and car, health, home, travel, and protection insurance policies. Further, Prudential plc provides fund man agement services for individual and institutional clients. The company was founded in 1848 and is based in London, the United Kingdom.
Advisors' Opinion:- [By Patricio Kehoe]
In fact, today the company announced that it will be launching a new universal life product for the Canadian market called Manulife UL by May 26 of this year. The new product will offer cost-effective insurance protection, as well as the opportunity for tax-advantaged investing, catering to customer�� demands for a more simplified insurance solution, which should help boost sales to some extent. Although the firm�� balance sheet is highly leveraged, exposing it to possible damages in the case of higher-than-expected policy liabilities, Manulife�� capital position has improved substantially over the past year. With a ratio of regulatory capital to capital required at 248%, the firm possesses excessive capital levels, well above competitors like Prudential Public Limited Company (ADR) (PUK), China Life Insurance Company Ltd. (ADR) (LFC), and Sun Life Financial Inc. (USA) (SLF), which all sport a 200% ratio. Moreover, the company�� excessive capital should allow it to maintain the above average dividend yield of 2.66% offered to shareholders.
- [By David O��ara]
Prudential
Back in January, analysts were forecasting that�Prudential� (LSE: PRU ) (NYSE: PUK ) �would make EPS for the year of 77.1 pence per share. Following a series of steady upgrades, that figure is now 83.6 pence. - [By Rupert Hargreaves]
Today, I am looking at�Prudential� (LSE: PRU ) (NYSE: PUK ) to determine whether you should consider buying the shares at 1,097p.
- [By David O��ara]
Prudential
Shares in insurer�Prudential� (LSE: PRU ) (NYSE: PUK ) are up 51% in the last 12 months. In that time, the FTSE 100 is 16.7% ahead.
Best Safest Stocks For 2014: iShares MSCI Philippines ETF (EPHE)
iShares MSCI Philippines ETF (the Fund), formerly iShares MSCI Philippines Investable Market Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the MSCI Philippines Investable Market Index (the Underlying Index). The Underlying Index is a free-float adjusted market capitalization weighted index designed to measure the performance of equity securities in the top 99% by market capitalization of equity securities listed on stock exchanges in the Philippines. Its sectors include financials, industrials, utilities, telecommunication services, consumer staples, consumer discretionary, materials, energy and S-T securities. Black Rock Fund Advisors acts as the Fund�� investment advisor. Advisors' Opinion:- [By Tom Aspray]
There is no question that it has been a rough few months for the Asian markets as since the October 9 low they have lagged behind the Spyder Trust (SPY), which is now up about 8.8%. Thailand (THD) has done the worst of the group, down over 13%, and the Philippines (EPHE) has also been weak since November.
Best Safest Stocks For 2014: Rapier Gold Inc (RPR)
Rapier Gold Inc. is a Canada-based gold focused exploration company. On March 12, 2013, the Company closed a share purchase agreement with two subsidiaries of Rio Tinto plc, which control rights to all non-talc minerals on mineral claims, Pen Gold North Project. The Pen Gold North Project is approximately 5,600 hectares in area and some of the claims are held through a lease and sublease with IMERYS. The combination of Pen Gold North and Pen Gold South properties comprise 16,448 hectares (approximately 160 square kilometers) located on the western extension of the Porcupine-Destor Deformation (Fault) Zone. The Company has executed the license and option agreement with Rogue Iron Corp. to explore for gold on the Pen Gold South property, which totals approximately 10,848 hectares, with an option to purchase those claims. These claims are part of a contiguous block with the Pen Gold North claims. Advisors' Opinion:- [By Holly LaFon]
Whitney George is Director of Investments, Managing Director, and a Portfolio Manager of Royce & Associates, LLC, investment advisor to The Royce Funds. He serves as portfolio manager for Royce Premier Fund (RPR), Royce Low-Priced Stock Fund (RLP), Royce Global Value Fund (RGV), Royce SMid-Cap Value Fund (RSV), and Royce Focus Trust (FUND). He also serves as assistant portfolio manager for Royce Micro-Cap Fund (RMC), Royce Value Fund (RVV), Royce Value Plus Fund (RVP), Royce Focus Value Fund (RFV), and Royce Capital Fund ��Micro-Cap Portfolio (RCM). Mr. George's thoughts in this interview concerning the stock market are solely his own and, of course, there can be no assurance with regard to future market movements.
Best Safest Stocks For 2014: Novartis AG (NVS)
Novartis AG, incorporated on February 29, 1996, provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company has five segments: Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals; vaccines and diagnostics, which include human vaccines and blood-testing diagnostics, and consumer health, which include over-the-counter medicines (OTC) and Animal Health. On April 8, 2011, the Company acquired the remaining non-controlling interest in Alcon, Inc. In December 2013, Alliance Pharma plc announced that its wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired all the United Kingdom and Republic of Ireland (ROI) rights to Lypsyl from Novartis AG.
In April 2011, Novartis sells global rights to Elidel, a medicine to treat atopic dermatitis to Meda. In March 2011, Novartis completes acquisition of majority stake in Zhejiang Tianyuan vaccines company in China. In March 2011, the Company acquired Genoptix, Inc. In October 2011, Novartis discontinues development of AGO178 for depressive disorder. In December 2011, the Company discontinues development of PRT128 for acute coronary syndrome and chronic coronary heart disease, and SMC021 for osteoporosis and osteoarthritis. In April 2011, Alcon's portfolio of generic ophthalmic medicines sold through its Falcon business unit primarily in the United States.
Pharmaceuticals Division
The Company�� Pharmaceuticals Division researches, develops, manufactures, distributes and sells patented prescription medicines in the therapeutic areas, such as Oncol! ogy; Primary Care, consisting of Primary Care medicines and Established Medicines, and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The Pharmaceuticals Division is organized into global business franchises responsible for the commercialization of various products, as well as Novartis Oncology, a business unit responsible for the global development and commercialization of oncology products, and Novartis Molecular Diagnostics, a business responsible for the development and commercialization of diagnostic tests and services related to its pharmaceuticals portfolio and therapeutic areas.
The Company�� Oncology products include Afinitor/Votubia, Exjade, Sandostatin SC/Sandostatin LAR , Femara , Zometa, Tasigna and Gleevec/Glivec. Gleevec/Glivec, which is a signal transduction inhibitor approved to treat patients with certain forms of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Tasigna is a signal transduction inhibitor of the tyrosine kinase activity of Bcr-Abl, KIT+ and the PDGF-receptor. Zometa is a treatment to reduce or delay skeletal-related events (SREs), including pathologic fracture, spinal cord compression, and/or requirement of radiation therapy or surgery to bone, in patients with bone metastases (cancer that has spread to the bones) from solid tumors and multiple myeloma. Femara is a once-daily oral aromatase inhibitor for the treatment of early stage or advanced breast cancer in postmenopausal women. Sandostatin SC/Sandostatin LAR is indicated for the treatment of patients with acromegaly, a chronic disease caused by over-secretion of pituitary growth hormone in adults. Sandostatin is also indicated for the treatment of patients with certain symptoms associated with carcinoid tumors and other types of gastrointestinal and pancreatic neuroendocrine tumors. Exjade is an oral iron chelator approved for the treatment of chronic iron overload due to blood transfusions in patients over ! two years! of age who have a range of underlying anemias. Patients with congenital and acquired chronic anemia, such as thalassemia, sickle cell disease and myelodysplastic syndromes, require transfusions, which puts them at risk of iron overload. Afinitor/Votubia is an oral inhibitor of the mTOR pathway.
The Company�� Primary Care products include Arcapta Neohaler/Onbrez Breezhaler, Diovan, Exforge, Tekturna/Rasilez, Galvus, Reclast/Aclasta, Voltaren/Cataflam, Ritalin, Ritalin LA, Focalin and Focalin XR. Its Specialty Care products include Lucentis, Gilenya, Exelon, Extavia and Comtan, and Stalevo. Its Integrated Hospital Care include Zortress/Certican, Ilaris, Neoral and Myfortic.The Company�� Critical Care products include Xolair and Tobi Podhaler. As of December 31, 2011, the products under development includes ACZ885, which is being investigated for the secondary prevention of cardiovascular events and for the treatment of Diabetes Mellitus; AEB071 (sotrastaurin) is a low molecular weight, selective inhibitor of protein kinase-C (PKC); AFQ056 (mavoglurant) is a metabotropic glutamate receptor 5 (mGluR5) antagonist in Phase II development for the treatment of Parkinson's disease levodopa-induced dyskinesia; AIN457 (secukinumab) is a human monoclonal antibody neutralizing interleukin-17A, a key pro-inflammatory cytokine expressed by TH17 cells and other types of white blood cells; BAF312 is an oral, second-generation sphingosine 1-phosphate receptor modulator in Phase II development for relapsing-remitting multiple sclerosis; DEB025 (alisporivir) is a cyclophilin inhibitor for the treatment of Hepatitis C virus infection (HCV); Gileny a line treatment for relapsing forms of MS; Exjade (deferasirox) is an oral iron chelator in development for use in patients with non-transfusion-dependent thalassemia (NTDT); INC424 (ruxolitinib) is an investigational Janus kinase (JAK) inhibitor, and Zortress/Certican (everolimus) is an mTOR inhibitor with immune/non-immune cell proliferation inhibition being d! eveloped ! for prevention of solid organ transplant rejection.
Alcon Division
The Company�� Alcon Division discovers, develops, manufactures, distributes and sells eye care products. Alcon is engaged in eye care with product offerings in Surgical, Ophthalmic Pharmaceuticals and Vision Care. In Surgical, Alcon develops, manufactures, distributes and sells ophthalmic surgical equipment, instruments, disposable products and intraocular lenses. In Pharmaceutical, Alcon discovers, develops, manufactures, distributes and sells medicines to treat chronic and acute diseases of the eye, as well as over-the-counter medicines for the eye. In Vision Care, Alcon develops, manufactures, distributes and sells contact lenses and lens care products.
Alcon's Surgical portfolio includes the Infiniti vision system for cataract procedures, the Constellation vision system for retinal operations, and the AcrySof family of intraocular lenses (IOLs), including the AcrySof IQ, AcrySof IQ ReSTOR, AcrySof IQ Toric and AcrySof IQ ReSTOR Toric IOLs. During the year ended December 31, 2011, its Alcon Division launched the LenSx femtosecond laser, a technology in cataract surgery, which increases the precision and reproductibility for corneal incisions, capsulorhexis and lens fragmentation steps of the procedure. In addition, Alcon provides advanced viscoelastics, surgical solutions, surgical packs and other disposable products for cataract and vitreoretinal surgery.
Alcon Division's Ophthalmic Pharmaceuticals business combines Alcon's range of pharmaceuticals with selected ophthalmic products (excluding Lucentis) previously marketed by the Novartis Pharmaceuticals Division. The products treat chronic and acute diseases of the eye including glaucoma and allergies, as well as anti-infective/anti-inflammatory and dry eye treatments. our Alcon Division's Ophthalmic Pharmaceuticals portfolio include Travatan Z solution and DuoTrav solution for the treatment of elevated intraocular pressure associ! ated with! glaucoma; Vigamox solution for bacterial conjunctivitis; Pataday solution for ocular itching associated with allergic conjunctivitis; and Nevanac suspension for eye inflammation following cataract surgery. Alcon launched a number of products during 2011, including Dailies Total 1 lenses, Opti-Free EverMoist Multi Purpose Disinfecting Solution, LenSx laser, AcrySof IQ ReSTOR Toric lens, AcrySof IQ Toric T6-T9 lens, Travatan BAK-free solution, DuoTrav BAK-free solution, Moxeza solution and Systane Balance eye drops.
Sandoz Division
The Company�� Sandoz Division is a global generic pharmaceuticals company that develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical and biotechnological active substances, which are not protected by valid and enforceable third-party patents. The Sandoz Division has activities in Retail Generics, Anti-Infectives, and Biopharmaceuticals and Oncology Injectables. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of pharmaceuticals, as well as supplying active ingredients to third parties. In Anti-Infectives, Sandoz develops and manufactures active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by retail generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products (biosimilars or follow-on biologics) and sells biotech manufacturing services to other companies.
In Oncology Injectables, Sandoz develops, manufactures and markets primarily cytotoxic products for the hospital market. During 2011, the Company launched generic docetaxel (Taxotere), higher-strength generic amlodipine-benazepril (Lotrel), generic meropenem (Merem) injection, and the formation of a women's health portfolio with generic Seasonale, Nordette, Yaz and Yasmin. The product launched in various European countries included generic docetaxel, ge! neric ana! strazole (Arimidex), and valsartan/covalsartan (an early entry generic version of Novartis Pharmaceuticals' Diovan/Co-Diovan).
Vaccines and Diagnostics Division
The Company�� Vaccines and Diagnostics Division researches, develops, manufactures, distributes and sells preventive vaccines and diagnostic tools. Novartis Vaccines is a global developer and manufacturer of human vaccines. Novartis Diagnostics is a blood testing and molecular diagnostics business dedicated to preventing the spread of infectious diseases through blood-screening tools that protect the world's blood supply. Novartis Vaccines' products include influenza, meningococcal, pediatric, adult and travel vaccines.
The Company�� influenza vaccines include Agrippal, Fluad, Fluvirin and Optaflu. Its Meningococcal Vaccines includes Menjugate and Menveo. Its travel vaccines include Encepur Children, Encepur Adults, Ixiaro and Rabipur/Rabavert. Its Pediatric Vaccines include Polioral and Quinvaxem.
Consumer Health
Consumer Health consists of two Divisions: OTC (over-the-counter medicines) and Animal Health. Each has its own research, development, manufacturing, distribution and selling capabilities. OTC offers readily available consumer medicine. Animal Health provides veterinary products for farm and companion animals.
OTC (over-the-counter medicines) offers products for the treatment and prevention of common medical conditions and ailments. OTC business focuses on a group of global brands in product categories that include treatments for cough/cold/respiratory (Triaminic, Otrivin, TheraFlu/NeoCitran), pain relief (Excedrin, Voltaren), digestive health (Benefiber, Prevacid24HR, Pantoloc Control), dermatology (Lamisil, Fenistil), and smoking cessation (Habitrol/Nicotinell).
Animal Health offers products and services focusing on both companion and farm animals (including cultivated fish). Key products for companion animals include Atopica (atopic dermatitis manageme! nt), Dera! maxx and Onsior (pain relief), Fortekor (heart failure in dogs, chronic renal insufficiency in cats), and Sentinel/Milbemax/Interceptor (intestinal parasite control and heartworm prevention), while farm animal products include the therapeutic anti-infective Denagard, an antimicrobial used to treat and control bacteria in swine, CLiK, an insect growth regulator used to control blowfly strike in sheep, cattle vaccines used to prevent respiratory and reproductive diseases in beef and dairy cattle, and Zolvix, a sheep drench representing the new sheep anthelmintic class. Aquaculture products include vaccines and treatments mainly used in salmon farming.
Advisors' Opinion:- [By Sara Ashley O'Brien]
Google has partnered with Alcon and Novartis (NVS) to make a smart contact lens that measures the glucose levels in diabetics' tears.
- [By Sean Williams]
So what: It's been a miserable day for Allergan, which started the day off by slightly lowering its full-year EPS forecast from a range of $4.75-$4.83 to $4.70-$4.76. To add the icing on the cake, its midday report that DARPin did show some differentiation from Novartis (NYSE: NVS ) and Roche's (NASDAQOTH: RHHBY ) Lucentis but didn't demonstrate enough to move the drug onto phase 3 trials, sent Allergan into the abyss. It probably doesn't help, either, that MAP's inhaled migraine drug Levadex, which Allergan acquired when it purchased MAP for nearly $1 billion earlier this year, also recently received its second complete response letter. Allergan just can't seem to catch a break.
- [By MONEYMORNING.COM]
The challenge is in finding a stock that has established a strong track record but still has room to grow. The big generics makers, like Teva Pharmaceuticals Industries Ltd. (NYSE ADR: TEVA), (Sandoz) Novartis AG (NYSE ADR: NVS), and Mylan Inc. (Nasdaq: MYL), sport market caps in the many billions of dollars. They've already seen most of their upside- particularly now, with fewer patents closing out next year.
- [By WALLSTCHEATSHEET]
Novartis is a healthcare company that provides a number of healthcare products and services to consumers and companies worldwide. Just recently, the company issued a positive earnings report, and offered good news for the rest of the year. The stock has been on a strong run, and is now consolidating near all-time high prices. Over the last four quarters, earnings have been improving, while revenue figures have been mixed, which has resulted in confused investors. Relative to its peers and sector, Novartis has been an average year-to-date performer. Look for Novartis to OUTPERFORM.
Best Safest Stocks For 2014: Banner Corporation(BANR)
Banner Corporation operates as the holding company for Banner Bank and Islanders Bank that provide commercial banking and financial products and services to individuals, businesses, and public sector entities. It generates various deposit instruments, including demand checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, regular savings accounts, certificates of deposit, cash management services, and retirement savings plans. The company also originates commercial business and commercial real estate loans, agricultural business loans, construction and land development loans, one to four-family residential loans, and consumer loans. In addition, it engages in mortgage banking operations primarily through the origination and sale of one to four-family residential loans. As of December 31, 2010, Banner Bank operated 86 branch offices and 7 loan production offices in Washington, Oregon, and Idaho; and Islanders Bank conducted business from 3 locations in San Juan County, Washington. The company was founded in 1890 and is based in Walla Walla, Washington.
Advisors' Opinion:- [By Diane Alter]
Dividend Stocks That Increased Payout in September
Accenture plc (NYSE: ACN) announced a 14.8%, or $0.12 per share, increase to its semiannual dividend. The management consulting firm will now pay a semiannual dividend of $0.93. Shares yield 2.53%. Agruim Inc. (NYSE: AGU) boosted its dividend by $1.00 per share to a total dividend of $3.00 on an annualized basis. Shares of the global retailer of agricultural products now sprout a 3.54% yield. Air Industries Group Inc. (NYSE: AIRI) doubled its dividend to $0.125 per share. The maker of airplane and helicopter parts now floats a lofty yield of 6.6%. Alexandria Real Estate Equities Inc. (NYSE: ARE) upped its dividend 4.6% to $0.68 per quarter for a yield of 4.21%. Banner Corp. (Nasdaq: BANR) boosted its quarterly dividend 25% to $0.15 per share. The parent company of Banner and Islander Bank serves the Pacific Northwest region. Brady Corp. (NYSE: BRC) lifted its quarterly dividend 2.6% to $0.78 per share. It was the 28th straight dividend increase from the identification solutions company. Shares yield 2.57%. Campbell Soup Co. (NSE: CPB) raised its quarterly dividend to $0.31 per share, up from $0.29. The company last raised its dividend in November 2010. Shares yield a hearty 3.06%. CLARCOR Inc. (NYSE: CLC) raised its quarterly dividend 26% to $0.17 per share. It's the largest percentage increase from the Tennessee-based diversified marketer of mobile filtration and packaging products in the last 20 years, and it continues the company's consecutive streak of increasing dividends for the last 30 years. Franklin Resources Inc. (NYSE: BEN) boosted its quarterly dividend 2.6% to $0.10 per share. Frisch's Restaurants Inc. (NYSE: FRS) increased its quarterly dividend 12.5% to $0.18. Shares yield 3.10% The Goodyear Tire & Rubber Company (NYSE: GT), in a move that suggests good times are ahead, reinstated its dividend at $0.05 per share. Good
No comments:
Post a Comment